LYON, France, Jun 26, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that Dr. Argil J. Wheelock, MD was appointed to its Board of Directors, effective June 25, 2009. Dr. Wheelock replaces Dr.

Ablatherm-HIFU Highlighted as Superior Non-Invasive Focal Therapy; Awarded Best Poster for Long-Term Focal Therapy Results

Jun 2, 2009 (GlobeNewswire via COMTEX News Network) -- Receives Ablatherm-HIFU Approval in Argentina Signs Exclusive Distribution Agreements in Argentina, Brazil and Chile LYON, France, June 2, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound,

May 13, 2009 (GlobeNewswire via COMTEX News Network) -- First Quarter 2009 Highlights: * FDA agreed changes to HIFU clinical trial protocol to accelerate enrollment * Continuing dialogue with FDA for further changes to ensure timely completion of HIFU trials for treatment of prostate cancer * Total

LYON, France, May 4, 2009 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its first quarter 2009 earnings announcement, which will take place on Wednesday, May 13, 2009, before the opening of the

Strong Cash Position of EUR 15.0 million (USD 20.8 Million)

High Intensity Focused Ultrasound Offers a Potentially Effective, Minimally Invasive Alternative to Existing Prostate Cancer Therapies

Recent Marketing Initiatives Result in 40% Growth in RPP Treatments

Supported by Expanding Physician Utilization of HIFU in Europe

Mar 31, 2009 (GlobeNewswire via COMTEX News Network) -- Fourth Quarter 2008 Highlights: * Record revenue of EUR 9.0 million, up 28.4% year-over-year and up 95.7% sequentially * Ablatherm-HIFU RPP treatments increased 31.9% year-over-year * Total HIFU revenue of EUR 3.4 million, up 13.9%